Severe ischemia following treatment with rituximab in a patient with mixed connective tissue disease: an unusual complication

Abstract

Get full access to this article

View all access options for this article.

References

Garcia-Carrasco M. , Mendoza-Pinto C. , Sandoval-Cruz M. , et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010; 19: 213-219.

Devauchelle-Pensec V. , Pennec Y. , Morvan J. , et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310-317.

McGonagle D. , Tan AL , Madden J. , et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford) 2008; 47: 552-553.

Haroon M. , O’Gradaigh D. , Foley-Nolan D. A case of Raynaud’s phenomenon in mixed connective tissue disease responding to rituximab therapy. Rheumatology 2007; 46: 718-719.

Eisenberg R. Update on rituximab. Ann Rheum Dis 2005; 64: iv55-iv57.

D’Arcy CA , Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44: 1717-1718.

Hellerstedt B. , Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14: 1792.

Todd DJ , Helfgott SM Serum sickness following treatment with rituximab. J Rheumatol 2007; 34: 430-433.

Finger E. , Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13: 94-95.

10.

Emery P. , Fleischmann R. , Filipowicz-Sosnowska A. , et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-1400.